Although he was quite dissatisfied with not being able to monopolize the venture, Executive Sato ultimately reached a cooperation agreement with Chen Yu.
Of course, this was not the outcome that Executive Sato had expected, but sharing a slice of the cake was always better than watching others eat while missing out himself, so he had to reluctantly accept it. Moreover, the interests involved in broad-spectrum anti-cancer agents were simply too significant!
To be honest, it was precisely because Chen Yu's venture was still in its infancy, and the development of broad-spectrum anti-cancer agents was only known within Japan, that the domestic pharmaceutical enterprises had a chance to share the cake.
If large international pharmaceutical enterprises became aware of this development, even Shunten-do would probably only be able to cry wolf, right?
